Aumolertinib (Aumseqa)
Treatment of non-small cell lung cancer in adults.
In 429 untreated patients with advanced EGFR-mutated NSCLC, aumolertinib prolonged median PFS versus gefitinib (19.3 vs 9.9 months; HR 0.46, 95% CI 0.36–0.60). Response rates and grade ≥3 adverse events were similar; rash and diarrhoea were less common. RCT · phase 3 · n = 429 · J Clin Oncol · 2022
Secondary analysis of the phase III AENEAS trial: in 106 patients with untreated EGFR-mutated advanced NSCLC and baseline CNS metastases, aumolertinib prolonged median CNS PFS vs gefitinib (29.0 vs 8.3 months; HR 0.31). No new safety findings. Secondary analysis · phase 3 · n = 106 · Cancer Commun (Lond) · 2024